ASCO ascent

Investors were keenly focused on immunotherapy combinations containing PD-1/L1 and IDO inhibitors going into this year’s American Society of Clinical Oncology meeting, but the biggest gainers were companies that generated positive clinical data for other mechanisms.

Between May 31, the day before companies began to issue announcements related to ASCO presentations, and the last day of the conference on June 6, at least six presenting companies gained 10% or more in share price. Three lost 10% or more (see “ASCO Movers”)...